Anuncia Medical Inc.

What Anuncia Medical Inc. does

Anuncia Medical Inc. (legal entity Anuncia Inc.) is a Scottsdale, Arizona-based privately held neurotherapeutic medical device company founded in 2018 that develops products for cerebrospinal fluid (CSF) management in hydrocephalus patients. Its core offering is the FDA-cleared ReFlow™ System Mini, an integrated platform comprising the ReFlow™ Mini Flusher — an implantable device positioned under the scalp that, when pressed, sends a controlled flush of fluid toward the shunt ventricular catheter to dislodge blockages — and a companion ReFlow™ Ventricular Catheter with a proprietary relief membrane that opens under flush pressure to create an alternate CSF flow pathway. The company is expanding its portfolio with the ReFlow® External Ventricular Drains (EVD) Flusher, which received FDA Breakthrough Device Designation in March 2025 for use in neurocritical care.

The company sells its devices exclusively by or on the order of a physician as prescription-only medical devices in the United States, using a direct enterprise field-sales motion targeted at neurosurgeons and treating clinicians. End users are predominantly pediatric or over-60 hydrocephalus patients in whom a large share of shunts fail within the first two years, primarily from occlusion — the failure mode ReFlow is engineered to address non-invasively at home or in clinic, potentially avoiding repeat revision brain surgeries. Revenue is generated through one-time device sales per implantation; no pricing is publicly disclosed and no revenue figures have been released.

Anuncia operates with 11–50 employees and is led by CEO and President Elsa Chi Abruzzo, with a board including medical device industry figures. The company maintains partnerships with the Hydrocephalus Association and other professional associations, has received a Flinn Foundation Grant (March 2025), and signals active fundraising through an Investor Relations page. The global hydrocephalus market is projected to grow from $6.90B in 2020 to $10.17B by 2030 (4.0% CAGR), with North America currently the largest regional share — though Anuncia is currently US-only, leaving international expansion as future optionality.

Name

Anuncia Medical Inc.

Legal name

Anuncia Inc.

Website

https://anunciainc.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

11–50 employees

Short description

Anuncia Medical Inc. is a Scottsdale, Arizona-based medical device company that develops FDA-cleared ReFlow™ implantable and EVD flushing devices to non-invasively clear cerebrospinal fluid shunt occlusions in hydrocephalus patients, sold exclusively through US prescribing neurosurgeons.

Ownership category

akta.pro rank

Product category

Neurosurgical / Hydrocephalus Treatment Devices

NAICS

Surgical Appliance and Supplies Manufacturing (339113)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Neurosurgical Implants & Cranial/CMF (Cranial Plates, Dural Repair, Shunts) (HLAHAEAD)

Keywords

• Hydrocephalus treatment devices
• Cerebrospinal fluid management
• Neurotherapeutic medical devices
• Shunt occlusion prevention
• Implantable CSF shunts

Headquarters

HQ city

Scottsdale

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Technology or R&D, Personnel, Marketing or Sales, Others

Revenue model

1. Medical Device Sales: Anuncia generates revenue through the sale of its FDA-cleared ReFlow™ System Mini and ReFlow™ Mini Flusher devices. These are prescription medical devices sold to hospitals and through physicians for implantation in hydrocephalus patients.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels8 records

Core offering

Anuncia Medical develops, manufactures, and sells FDA-cleared, prescription-only ReFlow™ neurotherapeutic devices for cerebrospinal fluid (CSF) management in patients with hydrocephalus. The ReFlow™ System Mini pairs an implantable Mini Flusher placed under the scalp with a ReFlow™ Ventricular Catheter featuring a proprietary relief membrane, enabling non-invasive clearing of shunt occlusions to help avoid repeat revision brain surgeries.

Product overview

Anuncia Medical Inc. offers a unified portfolio of neurotherapeutic devices centered on the ReFlow™ brand for cerebrospinal fluid (CSF) management. The core offering consists of the ReFlow™ System Mini, which includes the ReFlow™ Mini Flusher (an implantable device implanted under the scalp that can be pressed to flush blockages from shunt systems) and the companion ReFlow™ Ventricular Catheter (with a relief membrane backup feature). These FDA-cleared devices work together as an integrated shunt system to prevent and clear occlusions without requiring repeat revision brain surgeries. The company is expanding its portfolio with FDA Breakthrough Device Designation for the ReFlow® External Ventricular Drains (EVD) Flusher for critical care applications.

Differentiator

Problem solved

Functional benefit

Brands

• ReFlow™ System Mini: The only noninvasive way to attempt to restore, increase, or maintain CSF flow within a shunt system for patients with hydrocephalus.
• ReFlow™ Mini Flusher
• ReFlow™ Ventricular Catheter

Products and services

• ReFlow™ System Mini An FDA-cleared neurotherapeutic device offering the only noninvasive way to attempt to restore, increase, or maintain cerebrospinal fluid (CSF) flow within a shunt system. Designed to monitor, treat, and prevent shunt occlusions at-home or in-clinic for patients with hydrocephalus or conditions requiring CSF draining or shunting. Sold as a prescription medical device by or on the order of a physician in the United States.
• ReFlow™ Mini Flusher An implantable device placed under the patient's scalp as part of a shunt system; pressing it non-invasively sends a controlled flush of fluid toward the shunt ventricular catheter to push out blockages and open ventricular catheter flow holes. Indicated for patients with hydrocephalus or conditions requiring CSF draining or shunting, and intended for use by patients, caregivers, or clinicians to manage shunt occlusions without surgery.
• ReFlow™ Ventricular Catheter A ventricular catheter designed for use with the ReFlow Mini Flusher, featuring a relief membrane backup feature that can be opened by the flush to create an alternate pathway for CSF flow when blockages occur. Used in shunt systems for hydrocephalus patients.

Quantifiable outcome

• Large percentage of hydrocephalus shunts fail in first two years, mainly from occlusion

Segments2 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Scale indicators1 record

Recent moves6 records

Expansion highlights6 records

Direct peers

• Integra LifeSciences: Integra LifeSciences (Codman Specialty Surgical) is a leading manufacturer of hydrocephalus shunts, EVDs, and intracranial pressure monitoring devices—the most direct competitor to Anuncia's ReFlow portfolio. Both serve the same neurosurgery call point with implantable CSF management devices.
• B. Braun (Aesculap / Miethke): B. Braun's Aesculap division (via its partnership with Miethke) manufactures gravitational and programmable hydrocephalus valves and shunt systems. They compete head-to-head with Anuncia in the implantable CSF management market and have deep neurosurgeon relationships globally.
• Sophysa: Sophysa (France) is a specialist manufacturer of programmable hydrocephalus valves, shunts, and intracranial pressure monitors. They are a focused niche competitor comparable to Anuncia in scale and product specificity, targeting the same neurosurgery customer base.
• Spiegelberg: Spiegelberg (Germany) manufactures EVDs, ICP monitors, and CSF drainage systems used in neurosurgery and neurocritical care. They directly overlap with Anuncia's expanded ReFlow EVD Flusher product line.

Broad incumbents

• Medtronic: Medtronic's Hydrocephalus Therapy business (formerly Codman, acquired 2014) is the global market leader in CSF shunts, valves, and EVDs. Medtronic's neurosurgery division directly competes with Anuncia across the same patient population and surgeon call point, with dramatically broader scale and distribution.
• Natus Medical: Natus Medical provides neurology and neurosurgery-related devices and disposables, including products for hydrocephalus and CSF management. They are a broader incumbent with overlapping but non-identical product lines in the same neurosurgery market.

Emerging players

• Mölnlycke Health Care (CSF / Neurosurgery): Mölnlycke has expanded into neurosurgical drapes and single-use neurosurgery devices. While not a direct CSF management peer, they participate in the same neurosurgery OR ecosystem where Anuncia's ReFlow devices are implanted.
• Penumbra: Penumbra is a neurovascular device company with growing presence in the neurosurgery/neurocritical care market. While focused on stroke and thrombectomy, they participate in the same neurohospital call point as Anuncia's EVD Flusher extension.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/anunciainc
• Facebookfacebook.com/AnunciaInc
• LinkedInlinkedin.com/company/anuncia-inc
• Instagraminstagram.com/anunciamedical

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds3 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Anuncia Medical Inc.